The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

MET encodes a receptor tyrosine kinase c-MET for hepatocyte growth factor (HGF). The
specific combination of c-MET and HGF activates downstream signaling pathways to trigger …

Background Preclinical data suggest that EGFR tyrosine kinase inhibitors (TKIs) plus MET
TKIs are a possible treatment for EGFR mutation-positive lung cancers with MET-driven …

We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an
acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR …

Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide
and has a poor prognosis. Current treatments for advanced NSCLC included traditional …

Abstract Introduction MNNG HOS Transforming gene (MET) amplification and MET exon 14
(METex14) alterations in lung cancers affect sensitivity to MET proto-oncogene, receptor …

Background. c-MET is a receptor tyrosine kinase receptor (RTK) for the hepatocyte growth
factor (HGF). The binding of HGF to c-MET regulates several cellular functions …

Simple Summary Non-small cell lung cancer (NSCLC) remains a significant cause of death
worldwide, despite the significant progresses to date. Multiple molecular alterations have …

Introduction: The role of the c-mesenchymal-epithelial transition factor (c-MET) signaling
pathway in tumor progression and invasion has been extensively studied. C-MET inhibitors …